Veterinary Reference Laboratory Market Size & Share 2026-2035

Veterinary Reference Laboratory Market Size

The global veterinary reference laboratory market was valued at USD 5.6 billion in 2025 and is projected to reach USD 10.5 billion by 2035, advancing at a CAGR of 6.6%.

Reference laboratories concentrate the specialist infrastructure required for molecular testing, microbiology, toxicology, pathology, and high-volume panel processing that most individual practices cannot maintain economically. Demand therefore combines discretionary companion-animal diagnostics with mandated livestock surveillance, export certification, and outbreak response.

North America accounted for USD 2,510.2 million, or 44.6%, of global revenue in 2025 and is projected to reach USD 4,461.5 million by 2035 at a 6.1% CAGR. Europe represented USD 1,554.1 million, or 27.6%, while Asia Pacific represented USD 1,007.6 million, or 17.9%, and is projected to grow fastest at 7.7%. Latin America accounted for USD 354.7 million, or 6.3%, and Middle East & Africa represented USD 198.0 million, or 3.5%.

Companion animals generated USD 3,900.5 million, or 69.3%, of 2025 market revenue, compared with USD 1,724.3 million, or 30.7%, for livestock animals. This revenue mix reflects the scale of preventive testing, chronic-condition monitoring, and insurance-supported diagnostic workups in companion practice, while livestock demand is shaped more directly by surveillance programs, herd economics, and disease-control requirements. U.S. households owned pets in 66% of homes in 2023–2024, supporting a broad base of veterinary encounters capable of generating laboratory submissions ^{[1]American Pet Products Association, Industry Trends and Stats, americanpetproducts.org}. Animal diseases also impose substantial production and trade risks; FAO estimates that they cost the global economy up to USD 300 billion annually .

Clinical chemistry was the largest technology segment at USD 1,619.6 million and 28.8% share in 2025, followed by immunodiagnostics at USD 1,273.0 million and 22.6%, hematology at USD 1,073.5 million and 19.1%, and molecular diagnostics at USD 904.2 million and 16.1%. Hematology is projected to expand at the fastest technology CAGR of 9.4%, whereas routine chemistry faces more direct substitution from increasingly capable in-clinic systems. Reference laboratories remain differentiated when testing requires pathologist review, culture and susceptibility interpretation, specialized molecular assays, or high-consequence disease confirmation.

North America's leading share reflects an established commercial and institutional testing ecosystem, while Asia Pacific's 7.7% CAGR signals that expanding urban pet ownership and food-animal biosecurity are developing in parallel. The strategic issue for laboratory operators is therefore not simply geographic expansion; it is whether they can build courier reach, accredited methods, and referring-veterinarian relationships before demand becomes concentrated around local network leaders.

Key Drivers

Companion-animal ownership expands the number of veterinary encounters from which laboratory demand can arise, but the commercial effect is strongest when ownership is coupled with preventive-care adoption. Mars reported that more than 56% of people globally identify as pet parents, based on a study covering more than 20,000 respondents across 20 countries ^{[3]Mars, Mars unveils the world's largest pet parent study, www.mars.com}. In the United States, pet-industry expenditure reached USD 158 billion in 2024, including USD 41.0 billion for veterinary care and product sales . As wellness testing and chronic-disease management become more common, laboratories benefit from repeat chemistry, hematology, endocrine, urinalysis, and infectious-disease submissions rather than relying solely on acute-care volumes.

Insurance adds another layer of diagnostic demand because it reduces the owner's immediate financial exposure to a complete workup. North American pet insurance written premium exceeded USD 5.2 billion in 2024, while the insured-pet population reached 7.03 million ^{[4]North American Pet Health Insurance Association, North American Pet Health Insurance Industry Market Reaches $5.2B in Written Premium, naphia.org}. The effect is particularly material for feline care, where the insured-cat population grew faster than insured dogs in 2024 . This supports the 7.3% CAGR projected for cats, which exceeds the 6.9% CAGR projected for dogs.

Livestock surveillance provides a separate demand mechanism. African swine fever remained present across four continents from January 2022 through November 2025, requiring ongoing testing and reporting across affected production systems . In the United States, USDA APHIS confirmed H5N1 genotype B3.13 in dairy cattle in March 2024 and subsequently implemented testing requirements for lactating dairy cattle moving interstate ^{[5]USDA APHIS, Highly Pathogenic Avian Influenza H5N1 Genotype B3.13 in Dairy Cattle: National Epidemiologic Brief, September 24, 2024, www.aphis.usda.gov}. Such events increase the value of PCR capacity, sample logistics, validated workflows, and laboratory-network participation because the testing requirement is driven by animal-health controls rather than ordinary veterinary purchasing behavior.

Key Restraints

Advanced diagnostics remain difficult to scale in markets where imported reagents, cold-chain requirements, skilled-labor shortages, and laboratory infrastructure increase the delivered cost of testing. WOAH has identified diagnostic-kit costs and shortages of trained personnel as material barriers to veterinary diagnostic access in many countries . The constraint is most consequential where owners or smallholder producers bear the testing expense directly, limiting the adoption of specialized molecular, toxicology, and genomic panels even when disease burden is significant.

Point-of-care systems also reshape the economics of routine reference-laboratory testing. In-clinic chemistry, hematology, urinalysis, and lateral-flow platforms provide results during the consultation, which can be decisive for straightforward cases where immediate treatment decisions are required. IDEXX's inVue Dx cellular analyzer and Zoetis's Vetscan OptiCell demonstrate how AI-supported in-clinic tools are moving beyond basic screening toward cellular analysis and complete blood count workflows. This pressure is most visible in routine chemistry and urinalysis, where global CAGRs of 5.4% and 5.0%, respectively, trail overall market growth.

The substitution effect is not uniform. Culture and susceptibility testing, confirmatory pathology, specialized toxicology, and high-consequence molecular surveillance require equipment, controls, validation, and interpretive expertise that are not efficiently replicated at the practice level. Reference laboratories must therefore defend value through test complexity, report quality, turnaround reliability, and integration with clinical workflows rather than attempting to compete solely on the price of a routine panel.

Hematology's 9.4% CAGR reflects this shift. Automated CBC output is increasingly available in clinics, yet morphology review and AI-enabled cellular interpretation create an opportunity to differentiate services by insight rather than turnaround time alone. Operators that integrate advanced interpretation into reports can preserve relevance as basic measurements decentralize; those reliant on routine panel processing face greater exposure to workflow substitution.

Veterinary Reference Laboratory Market Segment Analysis

By Technology

Clinical chemistry

Clinical chemistry generated USD 1,619.6 million, or 28.8%, of global revenue in 2025 and is projected to grow at a 5.4% CAGR. Its scale reflects its role in metabolic assessment, organ-function monitoring, endocrine evaluation, and pre-anesthetic workups. North American clinical chemistry accounted for USD 724.7 million, or 28.9% of regional revenue, with a 4.8% CAGR. The slower growth profile reflects routine-panel migration to in-clinic analyzers, although multi-parameter panels and reflex testing continue to support reference-laboratory demand.

Immunodiagnostics

Immunodiagnostics represented USD 1,273.0 million, or 22.6%, and is projected to grow at 6.7%. ELISA accounted for USD 661.1 million, or 51.9%, with a 6.6% CAGR; LFA represented USD 468.4 million, or 36.8%, with a 7.1% CAGR; and other immunodiagnostic technologies accounted for USD 143.5 million, or 11.3%, with a 6.0% CAGR. In North America, immunodiagnostics generated USD 573.6 million, or 22.9%, at a 6.3% CAGR, including ELISA at USD 298.5 million, LFA at USD 211.7 million, and other assays at USD 63.3 million. ELISA retains importance in scalable serology and surveillance, while LFA growth reflects its fit with rapid screening workflows.

Molecular diagnostics

Molecular diagnostics accounted for USD 904.2 million, or 16.1%, of global revenue and is projected to grow at 6.0%. PCR represented USD 610.8 million, or 67.6%, at a 5.9% CAGR; microarray accounted for USD 205.4 million, or 22.7%, at a 6.6% CAGR; and other molecular methods contributed USD 88.0 million, or 9.7%, at a 5.4% CAGR. North American molecular diagnostics generated USD 405.9 million, or 16.2%, at a 5.4% CAGR, including PCR at USD 274.7 million, microarray at USD 92.7 million, and other methods at USD 38.5 million. Molecular testing is particularly exposed to regulatory and outbreak-related demand because PCR methods are central to pathogen detection and surveillance-network workflows ^{[5]USDA APHIS, Highly Pathogenic Avian Influenza H5N1 Genotype B3.13 in Dairy Cattle: National Epidemiologic Brief, September 24, 2024, www.aphis.usda.gov}.

Hematology

Hematology generated USD 1,073.5 million, or 19.1%, in 2025 and is forecast to grow at 9.4%, the highest CAGR among technologies. North America accounted for USD 481.7 million, or 19.2%, and is projected to grow at 8.8%. The growth case rests on the wider use of cellular analysis in routine wellness and urgent care, alongside demand for pathologist-supported interpretation in complex cases.

Urinalysis

Urinalysis represented USD 501.4 million, or 8.9%, and is projected to grow at 5.0%. Routine dipstick and sediment analysis are increasingly accessible in-clinic, but urine protein quantification, culture, and susceptibility testing retain a reference-laboratory role. Other technologies generated USD 253.0 million, or 4.5%, at a 5.7% CAGR and include specialized cytology, coagulation, endocrinology, genomics, and toxicology-related services.

By Application

Clinical pathology

Clinical pathology led applications with USD 1,842.1 million, or 32.8%, and is projected to grow at 6.9%. North American clinical pathology generated USD 819.2 million, or 32.6%, at a 6.3% CAGR. The application combines chemistry, hematology, urinalysis, cytology, and endocrine testing, making it the principal laboratory pathway for wellness screening and chronic-condition management.

Bacteriology

Bacteriology represented USD 823.8 million, or 14.6%, and is forecast to grow at 6.5%. Culture and susceptibility workflows remain important for antimicrobial stewardship because treatment decisions depend on organism identification and sensitivity interpretation. Antech offers microbiology services that include MALDI-TOF identification and antimicrobial susceptibility reporting ^{[6]Antech Diagnostics, Veterinary Microbiology Lab Services for Pets, www.antechdiagnostics.com}.

Virology

Virology generated USD 710.8 million, or 12.6%, and is projected to grow at 7.3%; North America represented USD 314.2 million, or 12.5%, at a 6.7% CAGR. Virology growth is supported by outbreak surveillance, food-animal disease controls, and companion-animal pathogen panels. Parasitology accounted for USD 624.1 million, or 11.1%, with a 6.3% CAGR, supported by fecal testing, vector-borne disease screening, and parasite identification.

Productivity testing

Productivity testing represented USD 469.6 million, or 8.4%, and is forecast to grow at 6.0%. Pregnancy testing generated USD 393.1 million, or 7.0%, and is projected to grow at 7.6%, the fastest application CAGR. Toxicology testing accounted for USD 442.4 million, or 7.9%, at a 5.6% CAGR. These applications are tied to herd economics, reproductive management, residue monitoring, and the need to establish causation in exposure events. Other applications generated USD 318.6 million, or 5.7%, and are projected to expand at 5.8%.

By Animal Type

Companion animals

Companion animals accounted for USD 3,900.5 million, or 69.3%, of global revenue and are projected to grow at 6.9%. Dogs generated USD 2,130.6 million, or 54.6% of companion-animal revenue, at a 6.9% CAGR. Cats represented USD 1,199.6 million, or 30.8%, and are projected to grow at 7.3%; horses accounted for USD 441.2 million, or 11.3%, at 6.3%; and other companion animals represented USD 129.1 million, or 3.3%, at 4.9%.

North American companion animals generated USD 1,743.7 million, or 69.5% of regional revenue, with a 6.4% CAGR. Dogs represented USD 954.4 million, or 54.7%, cats accounted for USD 538.3 million, or 30.9%, at a 6.7% CAGR, horses generated USD 199.3 million, or 11.4%, and other companion animals represented USD 51.8 million, or 3.0%.

Livestock animals

Livestock animals accounted for USD 1,724.3 million, or 30.7%, and are projected to grow at 6.0%. Cattle generated USD 728.2 million, or 42.2%, at a 6.1% CAGR; swine represented USD 426.3 million, or 24.7%, at 6.6%; poultry accounted for USD 368.3 million, or 21.4%, at 5.6%; sheep & goats generated USD 153.4 million, or 8.9%, at 5.2%; and other livestock represented USD 48.1 million, or 2.8%, at 4.6%.

North American livestock generated USD 766.5 million, or 30.5%, with a 5.5% CAGR. Cattle accounted for USD 325.1 million, or 42.4%; swine represented USD 190.2 million, or 24.8%; poultry generated USD 164.4 million, or 21.5%; sheep & goats accounted for USD 69.0 million, or 9.0%; and other livestock represented USD 17.8 million, or 2.3%. Livestock testing is less dependent on individual owner spending and more dependent on the economic consequences of disease, reproduction, movement, and market access.

The fastest-growing animal cohorts also reveal distinct demand patterns. Cats grow at 7.3% as insurance coverage and feline-specific clinical attention expand, whereas swine testing grows at 6.6% because transboundary disease surveillance remains a continuing operational requirement. These drivers require different commercial models: companion-animal laboratories need practice integration and clear clinical reporting, while livestock providers need validated surveillance capacity, logistics, and trusted relationships with producers and authorities.

Veterinary Reference Laboratory Market Regional Analysis

North America

North America generated USD 2,510.2 million, or 44.6%, of global revenue in 2025 and is projected to grow at a 6.1% CAGR. The U.S. represented USD 2,285.3 million, or 91.0% of the regional market, and is projected to grow at 6.0%; Canada accounted for USD 224.9 million, or 9.0%, and is forecast to grow at 6.7%. The region combines commercial networks with the USDA APHIS National Animal Health Laboratory Network, which provides coordinated diagnostic capacity for animal-health surveillance ^{[7]USDA APHIS, National Animal Health Laboratory Network: About, www.aphis.usda.gov}. Its mature laboratory infrastructure, insurance expansion, and government testing requirements create both recurring practice demand and a baseline of institutional volume.

Europe

Europe represented USD 1,554.1 million, or 27.6%, of global revenue and is projected to grow at 6.8%. Germany is supported by a large companion-animal base and extensive official diagnostic infrastructure. The Friedrich-Loeffler-Institut serves as Germany's federal research institute for animal health and as a national reference laboratory for more than 70 notifiable animal diseases ^{[8]Friedrich-Loeffler-Institut, National Reference Laboratories, www.fli.de}. Laboklin provides veterinary diagnostic services across Europe, while GD Animal Health operates diagnostic and monitoring services from the Netherlands. The UK is supported by APHA Scientific's reference capabilities and external quality-assurance operations . France, Italy, Spain, and Netherlands add demand through companion diagnostics, livestock surveillance, and national laboratory programs.

Asia Pacific

Asia Pacific generated USD 1,007.6 million, or 17.9%, of global revenue and is projected to grow at 7.7%. China, Japan, India, Australia, and South Korea combine growing companion-animal populations with major livestock and export-testing requirements. Healthforanimals reported substantial pet-population growth across Asian markets, including South Korea and China . The region's growth depends on whether testing infrastructure, sample transport, trained personnel, and method validation can keep pace with clinical demand. Markets with export-oriented livestock systems, particularly Australia, also sustain laboratory demand through certification and disease-control protocols.

Latin America

Latin America accounted for USD 354.7 million, or 6.3%, and is forecast to grow at 7.2%. Brazil is the principal regional contributor because of its large companion-animal population and livestock industry. Vaxxinova's acquisition of Brazilian diagnostic laboratory Labovet in December 2025 indicates growing interest in regional diagnostic capacity and livestock-health platforms . Mexico and Argentina contribute through both companion practice and cattle-related testing requirements.

Middle East & Africa

Middle East & Africa represented USD 198.0 million, or 3.5%, and is projected to grow at 5.8%. South Africa has the region's more developed veterinary infrastructure, while Saudi Arabia and UAE support demand related to food security, urban companion-animal care, and specialized animal-health programs. Reagent imports, laboratory staffing constraints, and uneven logistics limit the speed at which regional demand can convert into routine testing volumes .

Latin America's 7.2% growth is linked to the interaction between companion care and livestock production, while Middle East & Africa remains constrained by access conditions despite genuine disease-surveillance needs. Companies entering faster-growth regions must therefore match their operating model to local diagnostic pathways. A network built for urban companion clinics is not automatically suited to export-testing requirements or government-led surveillance contracts.

Veterinary Reference Laboratory Market Share & Competitive Landscape

Competition is shaped by the ability to combine laboratory testing with instruments, software, logistics, and specialist interpretation. Antech Diagnostics, operating within Mars Science & Diagnostics, offers reference-laboratory services and has expanded its presence in the UK and Europe ^{[9]Antech Diagnostics, About Us, www.antechdiagnostics.com}. Its competitive position rests on network scale and the ability to connect laboratory results with broader diagnostic and practice-support services.

APHA Scientific operates as the commercial arm of the UK Animal and Plant Health Agency and provides animal-health science, diagnostic services, and proficiency testing . Colorado State University Veterinary Diagnostic Laboratories provide multi-species diagnostic services and participate in disease-detection activities with state and federal partners . Cornell University College of Veterinary Medicine's Animal Health Diagnostic Center is a Level 1 NAHLN laboratory and provides broad diagnostic coverage, including molecular diagnostics, pathology, toxicology, and infectious-disease testing .

Friedrich-Loeffler-Institut combines official reference-laboratory functions with animal-health research and high-consequence disease capabilities ^{[8]Friedrich-Loeffler-Institut, National Reference Laboratories, www.fli.de}. GD Animal Health performs diagnostic analyses and operates livestock disease-monitoring programs in the Netherlands . Laboklin serves European veterinary practices through laboratory services spanning pathology, genetics, clinical chemistry, and microbiology .

IDEXX Laboratories operates a global companion-animal diagnostics platform that includes reference laboratories and in-clinic systems. IDEXX reported 2024 revenue of USD 3,898 million, with Companion Animal Group Diagnostics recurring revenue increasing 7% organically . Its inVue Dx cellular analyzer and Cancer Dx canine lymphoma panel demonstrate the company's strategy of connecting in-clinic diagnostics with reference-laboratory services.

Neogen Corporation participates through animal-safety products and genomics services. Its Animal Safety segment generated USD 268.9 million of FY2024 revenue . Texas A&M Veterinary Medical Diagnostic Laboratory offers more than 650 tests across 11 laboratory sections and supports routine diagnostics, disease surveillance, and export-related services .

Virbac generated consolidated revenue of €1,397.5 million in 2024 and serves companion- and farm-animal markets through a broad animal-health portfolio that includes diagnostic activities . Zoetis generated USD 9.3 billion in 2024 revenue and is extending its diagnostics strategy across in-clinic and reference-laboratory channels . Its November 2025 acquisition of Veterinary Pathology Group expanded its laboratory footprint in the UK and Ireland .

The competitive advantage of commercial networks increasingly depends on retaining the referring practice across multiple diagnostic touchpoints. Academic and public laboratories remain indispensable where official designation, outbreak response, or specialized expertise is required. As a result, consolidation does not eliminate institutional laboratories; instead, it changes the boundary between commercial routine testing and high-consequence or regulated diagnostic work.

Recent Industry Developments

Zoetis acquired Veterinary Pathology Group in November 2025. The acquisition expanded Zoetis's reference-laboratory presence across the UK and Ireland and complemented its in-clinic diagnostics portfolio .

IDEXX announced Cancer Dx in January 2025. The canine lymphoma panel became available through IDEXX Reference Laboratories in the U.S. and Canada from March 2025, extending the company's oncology-testing offering .

Zoetis launched Vetscan OptiCell in January 2025. The cartridge-based, AI-powered hematology analyzer was introduced at VMX 2025, increasing the capability of in-clinic CBC workflows .

IDEXX initiated global shipping of inVue Dx in late 2024. The slide-free cellular analyzer uses AI-supported analysis for in-clinic cellular testing and raises the performance threshold for routine diagnostic workflows .

Vaxxinova acquired Labovet in December 2025. The transaction strengthened Vaxxinova's diagnostic footprint in Brazil, particularly in animal-health markets linked to cattle and poultry production .

USDA APHIS implemented dairy-cattle H5N1 testing controls in 2024. The response to H5N1 detections in dairy cattle created testing requirements for interstate movement of lactating dairy cattle and increased the importance of networked molecular diagnostic capacity .

IDEXX expanded the Catalyst platform with a cortisol test in June 2025. The launch added real-time quantitative cortisol testing for canine endocrine evaluation to the Catalyst menu .